- Hawaiian Electric Industries, Inc. was recently added to the Russell 2000 Value-Defensive Index and the Russell 2000 Defensive Index, while multiple directors received compensation-related stock grants under the HEI 2011 Nonemployee Director Stock Plan at no cash cost.
- The index inclusions can broaden the shareholder base through benchmark-tracking funds, while the equity awards further align board compensation with long-term shareholder interests.
- Next, we'll examine how Hawaiian Electric Industries' inclusion in the Russell 2000 defensive indexes may influence its existing investment narrative.
We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Hawaiian Electric Industries Investment Narrative Recap
To own Hawaiian Electric Industries you need to believe its core Hawaii utility can manage wildfire liabilities while steadily improving balance sheet health and earnings quality. The new Russell 2000 defensive index inclusions highlight how the market currently views HEI as a more defensive name, but they do not materially change the key near term catalyst of legislative and regulatory progress on wildfire cost recovery, or the biggest risk that large remaining wildfire related obligations keep pressuring cash flow and leverage.
Among the recent updates, the March 2026 stipulation of settlement for stockholder derivative actions, with US$100,000,000 funded by insurers and a related US$47.75 million securities settlement, is most relevant here. It illustrates how HEI is still working through legal overhangs in parallel with index inclusions, and it feeds directly into the same catalysts and risks investors are watching around litigation resolution, funding plans and the company’s ability to keep investing in grid resilience.
Yet while index inclusion may look reassuring, investors still need to understand how wildfire liabilities could constrain cash flow and balance sheet flexibility...
Read the full narrative on Hawaiian Electric Industries (it's free!)
Hawaiian Electric Industries' narrative projects $3.4 billion revenue and $233.2 million earnings by 2029. This requires 3.5% yearly revenue growth and about a $106 million earnings increase from $126.9 million today.
Uncover how Hawaiian Electric Industries' forecasts yield a $13.75 fair value, in line with its current price.
Exploring Other Perspectives
Some of the most optimistic analysts already expected HEI to reach about US$4.0 billion in revenue and roughly US$108.8 million in earnings, yet the fresh defensive index status and ongoing wildfire risks you see now could either reinforce or challenge that far more upbeat view, so it is worth exploring how differently you might weigh these moving pieces.
Explore 5 other fair value estimates on Hawaiian Electric Industries - why the stock might be a potential multi-bagger!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Hawaiian Electric Industries research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Hawaiian Electric Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hawaiian Electric Industries' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com